CTOs on the Move

Equian

www.equian.com

 
One of our nation’s most pressing challenges is the rising cost and affordability of healthcare. At Equian, our efforts are dedicated to addressing this challenge. We provide solutions that ensure each healthcare interaction is paid accurately and at the lowest possible cost. We have a proven system to reduce healthcare cost through proprietary data analytics coupled with deep domain expertise. Once we have aligned with you and analyzed all of the data, we provide integrated payment integrity solutions that eliminate unnecessary spending.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.equian.com
  • 5975 Castle Creek Pkwy Suite 100
    Indianapolis, IN USA 46250
  • Phone: 800.962.6831

Executives

Name Title Contact Details
Mark Coderre
 Chief Information Security Officer Profile

Similar Companies

Nashville General Hospital at Meharry

Nashville General Hospital at Meharry is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Nashville General Hospital at Meharry is based in Nashville, TN. You can find more information on Nashville General Hospital at Meharry at www.nashvilleha.org

AppleCare Medical Group

AppleCare Medical Group is a Artesia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

M2 Communications

M2 Communications is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ELPRO SERVICES

ELPRO SERVICES is a Marietta, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.